Want to see NTHI full AI Analyst Report?
Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.00
▼(-36.58% Downside)
Action:Reiterated
Date:09/28/26
The score is held down primarily by extremely weak financial performance (minimal revenue, large and worsening losses, heavy cash burn, and deeply negative equity). Technicals also remain unfavorable with price below key moving averages and bearish momentum. Offsetting factors include positive clinical/regulatory progress and insider buying, but valuation support is limited given ongoing losses and no stated dividend yield.
Positive Factors
Positive Phase 2a NEO100 efficacy
The Phase 2a result provides meaningful clinical validation in recurrent IDH1-mutant glioma, where treatment options are limited. If confirmed in further studies, the demonstrated disease control could support regulatory advancement, improve partnering potential, and establish NEO100 as a differentiated CNS oncology asset.
Negative Factors
Minimal revenue and widening losses
The company remains pre-commercial, with negligible revenue and losses far ahead of current operating scale. This limits internal funding capacity and leaves future financial performance dependent on successful clinical development and eventual commercialization, making sustained profitability a distant and execution-sensitive outcome.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2a NEO100 efficacy
The Phase 2a result provides meaningful clinical validation in recurrent IDH1-mutant glioma, where treatment options are limited. If confirmed in further studies, the demonstrated disease control could support regulatory advancement, improve partnering potential, and establish NEO100 as a differentiated CNS oncology asset.
Read all positive factors
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.13M
Dividend YieldN/A
Average Volume (3M)183.55K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue Growth-100.00%
EPS Growth18.94%
CountryUS
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.22
Shares Outstanding28,805,380
10 Day Avg. Volume153,415
30 Day Avg. Volume183,552
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.91K
Enterprise Value/Ebitda-2.52
Forecast
1Y Price Target
$18.33Price Target Upside287.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
Company Description
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded ...
NeOnc Technologies Holdings, Inc. Financial Statement Overview
Summary
Income Statement
4
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| Gross Profit | -57.52K | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| EBITDA | -43.63M | -59.61M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -47.20M | -62.15M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 5.23M | 2.82M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 1.97M | 58.73K | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 328.22K | 6.31M | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 23.76M | 20.33M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -18.53M | -17.51M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | ||||||
| Free Cash Flow | -21.16M | -20.86M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -21.16M | -20.36M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 23.51M | 20.86M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Technical Analysis
Negative
4.73
Price Trends
3.86
Negative
4.20
Negative
6.02
Negative
Market Momentum
-0.28
Positive
37.40
Neutral
4.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTHI, the sentiment is Negative. The current price of 4.73 is above the 20-day moving average (MA) of 3.36, above the 50-day MA of 3.86, and below the 200-day MA of 6.02, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 37.40 is Neutral, neither overbought nor oversold. The STOCH value of 4.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTHI.
NeOnc Technologies Holdings, Inc. Risk Analysis
NeOnc Technologies Holdings, Inc. disclosed 83 risk factors in its most recent earnings report. NeOnc Technologies Holdings, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeOnc Technologies Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | $86.13M | -1.32 | 309.09% | ― | -100.00% | 18.94% | |
45 Neutral | $11.01M | -0.06 | -443.08% | ― | ― | 75.09% | |
42 Neutral | $3.97M | -0.02 | -372.86% | ― | ― | 53.95% | |
40 Underperform | $3.23M | -0.02 | -743.66% | ― | -100.00% | 77.63% |
* General Sector Average
NTHI
NeOnc Technologies Holdings, Inc.
2.92
-9.04
-75.59%
GOVX
GeoVax Labs
0.32
-14.05
-97.78%
GTBP
GT Biopharma
6.16
-11.50
-65.11%
CLDI
Calidi Biotherapeutics
1.05
-23.91
-95.79%
NeOnc Technologies Holdings, Inc. Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
NeOnc Plans FDA End-of-Phase 1 Meeting for NEO212
Positive
Sep 28, 2026
NeOnc Technologies announced on September 28, 2026, that it is scheduled to meet in person with the U.S. Food and Drug Administration on November 17, 2026, for an End-of-Phase 1 Type B meeting regarding its investigational CNS cancer therapy NEO21...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeOnc Simplifies Capital Structure Amid CNS Oncology Focus
Positive
Sep 21, 2026
NeOnc Technologies Holdings, Inc., a Nasdaq-listed, multi-Phase 2 clinical-stage biopharmaceutical company, is developing novel therapies for central nervous system cancers using its NEO platform to address blood-brain barrier challenges. Its lead...
Business Operations and StrategyPrivate Placements and Financing
NeOnc CEO Boosts Stake After Recent Offering
Positive
Sep 17, 2026
On September 16, 2026, NeOnc Technologies Holdings reported that Executive Chairman, President and CEO Amir F. Heshmatpour bought an additional 35,000 shares of company stock on September 15 for about $115,400 at a weighted average price of roughl...
Business Operations and StrategyPrivate Placements and Financing
NeOnc Technologies Announces $15 Million Registered Direct Offering
Positive
Sep 10, 2026
On September 8 and 9, 2026, NeOnc Technologies Holdings, Inc. entered into definitive securities purchase and placement agency agreements for a registered direct offering with new and existing healthcare-focused institutional investors. The deal c...
Executive/Board ChangesShareholder Meetings
NeOnc Technologies Holds 2026 Annual Stockholder Meeting
Positive
Aug 20, 2026
NeOnc Technologies Holdings, Inc. held its 2026 annual meeting of stockholders via live webcast on August 14, 2026, with 77.92% of eligible common shares represented, establishing a quorum under its bylaws. Stockholders elected two Class I directo...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeOnc Announces Positive Phase 2a Data in Brain Cancer
Positive
Aug 13, 2026
On August 12, 2026, NeOnc Technologies hosted an investor conference call to present top-line Phase 2a results from its NEO100-01 trial in recurrent IDH1-mutant high-grade glioma, reporting that the study met its primary endpoint with a median ove...
Business Operations and Strategy
NeOnc Technologies Reports Positive Phase 2a Glioma Results
Positive
Aug 12, 2026
On August 12, 2026, NeOnc Technologies reported positive topline Phase 2a results from its NEO100-01 study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, a setting with no approved targete...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
NeOnc Highlights Q2 Results and CNS Oncology Progress
Neutral
Aug 10, 2026
NeOnc reported its second-quarter 2026 results on August 10, 2026, alongside clinical and regulatory milestones for its NEO100 and NEO212 programs, underscoring a strategic focus on advancing central nervous system cancer treatments. The company c...
Business Operations and StrategyExecutive/Board Changes
NeOnc Technologies Adds New Director Amid Governance Focus
Neutral
Jul 2, 2026
On June 27, 2026, NeOnc Technologies director Ming-Fu (Alan) Chiang resigned from the company’s Board of Directors and Scientific Advisory Board, with the company stating his departure did not stem from any dispute over operations, policies,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.